<?xml version="1.0" encoding="UTF-8"?>
<p id="Par33">Enrolled subjects experienced an improvement in their symptoms, which was most notable at 1 month after treatment, and was sustained at 1 year in some cases (Table 
 <xref rid="Tab6" ref-type="table">6</xref>). The potential durable benefit of UCMSC at 1 month, and sustained in some measures to 1 year, is in stark contrast to current MS drug therapies, which are required to be taken daily or weekly [
 <xref ref-type="bibr" rid="CR36">36</xref>]. In addition, MS drugs are known to carry side effects [
 <xref ref-type="bibr" rid="CR37">37</xref>] not seen after UCMSC infusions up to 1-year after treatment. 
</p>
